RP-3 by Replimune for Lung Cancer: Likelihood of Approval

RP-3 is under clinical development by Replimune and currently in Phase I for Lung Cancer.

Study breaks down Alzheimer’s treatment effects in clear terms

In the past two years, the Food and Drug Administration has approved two novel Alzheimer’s therapies, based on data from clinical trials showing that both

February 13, 2025

Study: CKD Not Worsened With Gout Treatment

Worries that urate-lowering therapy (ULT) could speed renal failure in patients with gout and chronic kidney disease (CKD) are unfounded, data from Great Britain indicated.

November 26, 2024

Medicare enrollees can switch coverage now. Here’s what’s new and what to consider.

Consumers know it’s fall when stores start offering Halloween candy and flu shots — and airwaves and mailboxes are filled with advertisements for Medicare options.

October 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.